Gabriel Vega-Cornejo

Nov 1, 2024 | jrheum.org | Hermine I Brunner |Cesar Pacheco-Tena |Ingrid Louw |Gabriel Vega-Cornejo

RESULTSParticipant disposition and baseline characteristics. Of the 127 participants included in the GO-VIVA main study primary analysis set,7 112/127 (88.2%) continued into the LTE, 71/127 (55.9%) completed IV golimumab dosing at week 244, and 69/127 (54.3%) completed follow-up at week 252 (Figure 1). AEs were the most common reason for discontinuation through week 252, accounting for 24 of the 127 (18.9%) LTE participants.

Aug 8, 2024 | jrheum.org | Hermine I Brunner |Cesar Pacheco-Tena |Ingrid Louw |Gabriel Vega-Cornejo

Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label, Phase III Study Hermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, Simone Appenzeller, Vyacheslav Chasnyk, Thomas Griffin, Carmen Navarrete Suarez, Sheila Knupp-Oliveira, Andrew Zeft, Yonatan Butbul Aviel, Deirdre De Ranieri, Beth S. Gottlieb, Deborah M. Levy, C.

Jul 26, 2024 | jrheum.org | Hermine I Brunner |Cesar Pacheco-Tena |Ingrid Louw |Gabriel Vega-Cornejo

Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-term Extension of an Open-label, Phase 3 Study Hermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, Simone Appenzeller, Vyacheslav Chasnyk, Thomas Griffin, Carmen Navarrete Suarez, Sheila Knupp-Oliveira, Andrew Zeft, Yonatan Butbul Aviel, Deirdre De Ranieri, Beth S. Gottlieb, Deborah M. Levy, C.